Company Description
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3).
We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β.
We believe that the blockade of GSK-3β signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity.
We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU).
The lead drug in our portfolio is called elraglusib (9-ING-41), which is being evaluated in a randomized Phase 2 trial in patients with metastatic pancreatic cancer, our most advanced clinical indication to date.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Daniel Schmitt |
Contact Details
Address: 1751 River Run, Suite 400 Fort Worth, TX 76107 United States | |
| Phone | (817) 887-8455 |
| Website | actuatetherapeutics.com |
Stock Details
| Ticker Symbol | ACTU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001652935 |
| Employer ID | 47-3044785 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel M. Schmitt | President, Chief Executive Officer and Director |
| Andrew P. Mazar, Ph.D. | Chief Operating Officer |
| Paul Lytle | Chief Financial Officer |
| Aaron G.L. Fletcher, Ph.D. | Chairperson and Director |
| Les Kreis, Jr. | Director |
| Todd Thomson | Director |
| Dan Zabrowski, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2024 | FWP | Free Writing Prospectus |
| Jun 21, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 20, 2024 | 8-A12B | Registration of securities |
| Jun 11, 2024 | FWP | Free Writing Prospectus |
| Jun 11, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 24, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 13, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 30, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 9, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 6, 2024 | D | Notice of Exempt Offering of Securities |